The Administrative Core will provide management services to each of the Projects and Cores in this Program. The Core will provide financial, administrative, and clerical services for the PI, the Co-Pl, Project Leaders, and Core Leaders for all grant-related activities. These activities include preparation of this competing renewal, non-competing renewals including progress reports, preparation of budgets, communication with the NIH regarding renewals and all financial interactions, and assurance that the labs supported by this Program are in full compliance with all institutional, state and federal regulations. Core A will also coordinate and schedule all meetings related to the function of the Program, including monthly meetings of all Project and Core leaders, and members of their respective laboratories, as well as annual meetings of the Internal and External Advisory Boards. Core A will also coordinate efforts with Dr. Armstrong, the sole off-site investigator, to travel to meetings or teleconference. Dr. Ebert is the PI and Director of this Core, and will serve as the overall scientific director and chief administrator. Dr. Griffin is the Co-Pl and will assist in these operations, particularly with regard to clinical programs, core facilities, and samples at the DFCI. He will assist Dr. Ebert in monitoring protocol performance and will assist in protocol development. Chanel Logan is a highly skilled administrator with experience in management of fiscal and administrative matters for large program project grants. She will serve as Administrative Facilitator, manage budgets between participating institutions, prepare reports including non-competing renewals, interface with the financial officers of each participating institution in the Program, and serve as an interface between these groups and the NIH. In addition, the Administrative Core will assure compliance and appropriate regulations regarding experimentation with human subjects, (including gender and minority participation) and vertebrate animals.
The Administrative Core will provide management services to each of the Projects and Cores in this Program. The Core will provide financial, administrative, and clerical services for the Pl, the Co-Pl, Project Leaders, and Core Leaders for all grant-related activities.
|Townsend, Elizabeth C; Murakami, Mark A; Christodoulou, Alexandra et al. (2016) The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell 29:574-86|
|Arreba-Tutusaus, P; Mack, T S; Bullinger, L et al. (2016) Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. Leukemia 30:1220-5|
|Tanaka, Minoru; Roberts, Justin M; Seo, Hyuk-Soo et al. (2016) Design and characterization of bivalent BET inhibitors. Nat Chem Biol 12:1089-1096|
|Wu, H; Hu, C; Wang, A et al. (2016) Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia 30:173-81|
|Wu, H; Hu, C; Wang, A et al. (2016) Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia 30:754-7|
|Puram, Rishi V; Kowalczyk, Monika S; de Boer, Carl G et al. (2016) Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML. Cell 165:303-16|
|Brien, Gerard L; Valerio, Daria G; Armstrong, Scott A (2016) Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. Cancer Cell 29:464-76|
|Zhu, Nan; Chen, Mo; Eng, Rowena et al. (2016) MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest 126:997-1011|
|Schneider, Rebekka K; Schenone, Monica; Ferreira, Monica Ventura et al. (2016) Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9. Nat Med 22:288-97|
|Hatcher, John M; Weisberg, Ellen; Sim, Taebo et al. (2016) Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor. ACS Med Chem Lett 7:476-81|
Showing the most recent 10 out of 280 publications